A Study of MVA85A in Healthy Infants

This study has been completed.

Sponsor:

Collaborators:

University of Oxford

University of Cape Town

Information provided by (Responsible Party):

Aeras

ClinicalTrials.gov Identifier:

NCT00953927

First received: July 31, 2009

Last updated: April 25, 2016

Last verified: April 2016

History of Changes

Results First Received: October 23, 2013

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Prevention
Condition:	Tuberculosis
Interventions:	Biological: MVA85A/AERAS-485 Biological: Candida Skin Test Antigen

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Investigational Vaccine	MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
Control Group	Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.

Participant Flow: Overall Study

	Investigational Vaccine	Control Group
STARTED	1399	1398
COMPLETED	1294	1303
NOT COMPLETED	105	95
Lost to Follow-up	61	65
Withdrawal by Subject	36	25
Death	7	4
Other study discontinuation	1	1

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent to treat population

Reporting Groups

	Description
Investigational Vaccine	MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
Control Group	Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.
Total	Total of all reporting groups

Baseline Measures

	Investigational Vaccine	Control Group	Total
Number of Participants [units: participants]	1399	1398	2797
Age [units: participants]
<=18 years	1399	1398	2797
Between 18 and 65 years	0	0	0
>=65 years	0	0	0
Age [units: years] Mean (Standard Deviation)	.401 (.039)	.399 (.037)	.400 (.038)
Gender [units: participants]
Female	691	682	1373
Male	708	716	1424
Region of Enrollment [units: participants]
South Africa	1399	1398	2797

Outcome Measures

Show All Outcome Measures

1. Primary:

To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants. [ Time Frame: AEs recorded 28 days post-vaccination; SAEs recorded for entire study period. ]

Hide Outcome Measure 1

Measure Type	Primary
Measure Title	To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants.
Measure Description	Adverse events (AE) were collected for 28 days after vaccination. The subject's parent or guardian recorded information regarding occurrences of solicited adverse events in diary cards through 7 days after vaccination. Serious adverse events (SAE) were collected from the time of study vaccine dosing throughout the entire study. A safety cohort (the first 330 infants enrolled) also had serum chemistry and hematology testing up to 28 days post-vaccination.
Time Frame	AEs recorded 28 days post-vaccination; SAEs recorded for entire study period.
Safety Issue	Yes

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All subjects vaccinated.

Reporting Groups

	Description
Investigational Vaccine	MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
Control Group	Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.

Measured Values

	Investigational Vaccine	Control Group
Number of Participants Analyzed [units: participants]	1399	1396
To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants. [units: percentage of all subjects vaccinated] Number (95% Confidence Interval)	95.9 (94.7 to 96.8)	83.7 (81.7 to 85.6)

No statistical analysis provided for To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants.

2. Secondary:

To Evaluate the Efficacy of the MVA85A/AERAS-485 Vaccine Compared to Controls in Prevention of Tuberculosis Using an Endpoint Derived From Epidemiological Cohort Surveys in BCG Vaccinated Infants. [ Time Frame: 15 to 36 months post-vaccination ]

Show Outcome Measure 2

3. Secondary:

To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells. [ Time Frame: 28 days post-vaccination ]

Show Outcome Measure 3

4. Secondary:

To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the ex Vivo Enzyme Linked Immunospot (ELISPOT) Test Used in Previous MVA85A/AERAS-485 Human Trials. [ Time Frame: 7 days post-vaccination ]

Show Outcome Measure 4

5. Secondary:

To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay. [ Time Frame: 28 days post-vaccination ]

Hide Outcome Measure 5

Measure Type	Secondary
Measure Title	To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay.
Measure Description	Frequencies of CD4 and CD8 T cells expressing cytokines (IFN-γ, IL-2 and TNF-α) following stimulation of whole blood with an Ag85A peptide pool were also measured by flow cytometry for a subset of infants.
Time Frame	28 days post-vaccination
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Pre-specified population subset

Reporting Groups

	Description
Investigational Vaccine	MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
Control Group	Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.

Measured Values

	Investigational Vaccine	Control Group
Number of Participants Analyzed [units: participants]	17	19
To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay. [units: percentage of cytokine expressing cells] Median (95% Confidence Interval)
Percent IL2/IFN-gamma/TNF expressing CD4 cells	0.030 (0.022 to 0.079)	0.001 (0.000 to 0.001)
Percent IL2/IFN-gamma/ TNF expressing CD8 cells	0.000 (0.000 to 0.000)	0.000 (0.000 to 0.000)

No statistical analysis provided for To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay.

6. Secondary:

To Discover Correlates of Protection From Tuberculosis in Infants Vaccinated With MVA85A/AERAS-485. [ Time Frame: 15 to 36 months post-vaccination ]

Show Outcome Measure 6

7. Secondary:

To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial. [ Time Frame: 15 to 36 months post-vaccination ]

Show Outcome Measure 7

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Show More Information

To Top